Additional Information
Market: TSX
Sector: General Mining
EPIC: TSXC
Latest Price: 15,625.70  (0,00%)
52-week High: 0.00
52-week Low: 0.00
1 year chart
1 day chart

Trimel soars on FDA approval for nasal gel to treat testosterone-deficient men

29th May 2014, 10:53 am by Deborah Bacal
The Natesto gel, for which it has received U.S. regulatory approval today, is the first and only testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone, according to the company's statement. The Natesto gel, for which it has received U.S. regulatory approval today, is the first and only testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone, according to the company's statement.

Trimel Pharmaceuticals (TSE:TRL) surged on Thursday after news that it has received U.S. FDA approval for its Natesto testosterone nasal gel, extending gains from the previous session. 

Shares rose to as high as 92 cents during the morning hours, lately up at 89 cents, an increase of more than 25%. This week, the company's stock has risen more than 50%, buoyed by news on Wednesday that it received encouraging results from a phase II clinical trial of Tefina, a testosterone nasal gel designed to treat female orgasmic disorder. 

The Natesto gel, for which it has received U.S. regulatory approval today, is the first and only testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone, according to the company's statement.

The drug is self administered via a nasal applicator, minimizing the risk of secondary exposure to women and children.

"This novel route of administration will enable men to take this therapy in mere seconds, without worrying about the risk associated with transferring the product to women or children," said president and CEO Tom Rossi. 

"We are now focused on getting Natesto to market as expeditiously as possible so that appropriate patients can have access to it."

According to a company release, it is estimated that nearly 13 American men may have low testosterone levels, with current treatment options including topical gels, transdermal patches, intramuscular injections and oral tablets. 

"In my practice I regularly encounter men demonstrating symptoms of hypogonadism and physicians will increasingly see this as the North American population ages," said the medical director and founder of Clinical Research of South Florida, Dr. Jeffrey Rosen. 

"For these patients seeking to restore their testosterone levels, Natesto will offer an alternative delivery system that is safer and more convenient than the other options currently available on the market."

No investment advice


Proactive Investors North America Inc, trades as "Proactiveinvestors USA & Canada".


You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.


You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.


From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.


You understand that we may be providing advertising and/or marketing services to companies mentioned on the site. A full list of companies that are paying for services from us, or our affiliated companies in the UK and Australia can be viewed here